Higher Body Fat Linked to Higher Risk of Death From Prostate Cancer
Increases in waist-to-hip ratio, body mass index, waist circumference, and total body fat percentage were associated with increases in the risk of prostate cancer death.
Diagnosis & Disease Information
Risk of Cancer-Specific Death May Remain Elevated for 30 Years
Patients with certain cancers have an increased risk of cancer-specific mortality that persists for 30 to 35 years after diagnosis.
HRQOL Data Support First-Line Lenvatinib-Pembrolizumab in Advanced Renal Cell Carcinoma
The median time to definitive deterioration was longer with lenvatinib-pembrolizumab than with sunitinib.
Lymphopenia Tied to Risk of Infection After Radiotherapy
Measuring lymphocytes during or after radiotherapy could provide useful information about infection risk, according to researchers.
Sarcopenia and Inflammation Linked to Worse Survival in mRCC
Patients who had sarcopenia and an elevated neutrophil-to-lymphocyte ratio had the worst overall survival.
High Baseline Troponin T May Predict MACE After Treatment in Renal Cell Carcinoma
Patients who had high baseline troponin T levels had a more than 3-fold greater risk of MACE.
Olaparib Improves HRQOL in Prostate Cancer
Researchers assessed pain and HRQOL measures with olaparib vs physician’s choice of treatment in patients with prostate cancer.
Trimodal Therapy Appears Equivalent to Radical Cystectomy for Select MIBC Patients
The 5-year metastasis-free survival was similar with trimodal therapy and radical cystectomy.
Molecular Features of Primary and Metastatic Sites Differ in Renal Cell Carcinoma
New findings could inform personalized therapeutic strategies for patients with renal cell carcinoma, according to investigators.
Niraparib Maintenance Failed to Improve Outcomes in Advanced Urothelial Carcinoma
The median progression-free survival was similar between the treatment arms.
- Loading...
Loading...
Next post in Genitourinary Cancers Symposium
Loading... 
Loading...